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AgeingManipulation of diet such as increasing the level of fat or inducing insulin resistance has been shown to
exacerbate the pathology in several animal models of neurological disease. Caloric restriction, however, has
been demonstrated to extend the life span of many organisms. Reduced calorie consumption appears to
increase the resistance of neurons to intracellular and extracellular stress and consequently improves the
behavioural phenotype in animal models of neurological diseases, such as Alzheimer's disease. We review
the evidence from a variety of mouse models that diet is a risk factor that can signiﬁcantly contribute to the
development of neurological diseases.lopment, R&D China, GlaxoS-
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High calorie diet is a risk factor that can signiﬁcantly contribute to
the development of neurological disease. Conversely, caloriﬁc restric-
tion has been shown to reduce symptom progression of neurological
disorders, such as AD, suggesting that diet management is of
signiﬁcant importance to prevent or reduce the prevalence of
neurological diseases in the developing society. Importantly, this
key concept has been successfully recapitulated in mouse models of
neurological disease, where dietarymanipulations performed onmice
exhibiting “AD-like” pathology, for example, have identiﬁed critical
mechanisms/targets that contribute to, or potentially reduce the
development of disease and hence offer novel therapeutic strategies
relevant to disease prevention. This review will provide further
evidence to the clinical and epidemiological evidence linking high fat
diet to the risk of neurological disease by direct evidence resulting
from data generated in mouse models of disease. These studies have
elucidated novel mechanisms and targets that are regulated in
response to dietary manipulations and evaluating such targets and
pathways should provide future therapeutic opportunities for
patients.2. Dietary modulation
Numerous studies implicate certain cardiovascular risk factors as
key triggers for the onset and development of vascular-related
dementia [1]. Increasing evidence has conﬁrmed that abnormal levels
of cholesterol, or detrimental cholesterol metabolism, play a pivotal
role in the pathophysiology of Alzheimer's disease (AD). Epidemio-
logical and clinical studies have indicated that patients with elevated
levels of cholesterol have an increased susceptibility to AD [2] and AD
is more prevalent in countries with high-fat and high-calorie diets [3].
Furthermore, a large body of evidence indicates that dietary
conditions that promote the development of insulin resistance (IR)
may also increase the relative risk of AD. Importantly, epidemiological
studies suggest that IR as a consequence of Type II diabetes (T2D)
characterized by glucose intolerance, obesity and hyperinsulinemia is
associated with a 2- to 3-fold increased relative risk of AD,
independent of the risk for VaD [4,5]. These concepts have become
more poignant to date due to the rising prevalence rates of T2D,
obesity and AD over the last few decades. Approximately 24 million
people worldwide are now reported as having dementia, with the
prevalence rate predicted to double every 20 years [6]. Although
ageing is regarded as the strongest risk factor for developing AD,
emerging evidence suggests that dyslipidemia and T2D can contribute
signiﬁcantly to the pathogenesis of AD either via direct or indirect
mechanisms. Animal models relevant to AD in combination with
dietary manipulation have effectively supported this hypothesis and
have identiﬁed genes, targets and pathways that may be suitable for
future therapeutic intervention. Importantly a number of other
neurodegenerative disorders have been associated with impaired
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disease, Down's syndrome, Friedreich's ataxia, etc. [7], although
appropriate mouse models have not be rigorously evaluated to
determine the contribution of dietary manipulations on glucose
metabolism and progression of disease in relation to these syndromes.
However, AD-relevant mouse models have been used more exten-
sively to address the impact of dietary modiﬁcation on disease and
have provided useful insights into potential targets and pathways
which may have broader utility for other neurodegenerative/
neurological diseases. The next sections of this review will document
the evidence obtained from mouse models which highlight the
contribution of dietary modulation on pathophysiological and
neurological end-points relevant to AD and identify potential
opportunities for treatment.
Preclinical evidence for supporting a role for abnormal cholesterol
metabolism in the pathogenesis of ADwas initially conﬁrmed through
the use of hemizygous double mutant PSAPP mice, derived from
crossing hemizygous transgenic mice expressing familial AD human
mutant APPKG70N.M671L (Tg2576 line) [8] with a homozygous line of
mice expressing the human familial mutant PS1M146V (line 8.9) [9].
From 5 weeks of age, mice were either placed on a high-cholesterol
diet (containing 5% cholesterol, 10% fat, and 2% cholate and 5.2 kcal/g)
or a basal diet (containing 0.005% cholesterol and 10% fat and 3.6 kcal/
g) for 7 weeks [10]. The results from the study demonstrated that
diet-induced hypercholesterolemia in PSAPP transgenicmice elevated
both plasma and CNS cholesterol levels as well as increasing the
accumulation of Aβ in the CNS, relative to the basal diet. Importantly
signiﬁcant elevations in Aβ were measured by three independent
techniques (ELISA, IP/MS and IHC) and total Aβ (ELISA) correlated
positively with both increases in plasma and CNS cholesterol. The
hypothesis generated from this pivotal study implicated that
abnormal cholesterol levels/metabolism either increase APP proces-
sing or APP sorting which may have contributed towards accelerating
AD-relevant Aβ pathology in this transgenic line of mice. These
ﬁndings were subsequently conﬁrmed in an APP695 (K670N and
M671L) Swedish mutant mouse model of AD fed a high fat/
cholesterol diet for 7–10 months [11]. A more recent study [12]
attempted to evaluate the role of hypercholesterolemia on neuroin-
ﬂammation and APP processing in normal C57BL/6 mice and low-
density lipoprotein receptor (LDLR) deﬁcient mice and to determine
the functional consequences of this dietarymanipulation via cognitive
testing. Essentially each of the two strains of mice either received
normal chow (5% fat and 0.05% cholesterol) or high-fat/-cholesterol
(21%/1.25%) diet at 4 months of age for a period of 2 months. Mice
were evaluated in the 8-arm radial maze for cognitive performance in
the last 2 weeks of the 2 month dietary regime and then brains were
harvested to determine markers of neuroinﬂammation together with
Aβ. The results from this study conﬁrmed that a high-fat/-cholesterol
diet for 2 months increased plasma levels of both total and LDL-
associated cholesterol which was associated with working memory
impairments in both C57/BL6 and LDLR-deﬁcient mice. Importantly
the LDLR-deﬁcient mice showed a working memory deﬁcit regardless
of diet, suggesting the targeted disruption of the genewhich induces a
moderate hypercholestolemia was sufﬁcient in its own right to
contribute towards inducing a cognitive deﬁcit. Immunohistochem-
ical analysis revealed signiﬁcant microglial (CD45+ve) and astrocytic
(GFAP+ve) activation within the hippocampi of both C57/BL6 and
LDLR-deﬁcient mice fed a high-fat/-cholesterol diet together with
increased cytokine (TNFα, IL-1β, IL-6) and iNOS and Cox-2 gene
expression (via qRT-PCR). Interestingly increases in APP processing
(BACE1 expression and generation of APP CTFs) were also apparent in
both C57/BL6 and LDLR-deﬁcient mice fed a high fat/cholesterol diet.
Importantly, these results further support the signiﬁcant contribution
played by the adverse effects of a cholesterol-rich/high fat diet on
pathophysiological markers relevant to AD and conﬁrm the conse-
quent memory impairments in a non-familial AD mouse model.Clearly mouse models have contributed to our improved understand-
ing for the role of abnormal cholesterol metabolism in developing
cognitive impairments and neuropathological processes relevant to
disease and may offer an appropriate test bed to evaluate novel
therapeutic strategies (beyond statins (HMG-CoA reductase inhibi-
tors) which have provided mixed results in AD clinical trials) targeted
to reduce hypercholesterolemia [13,14].
The concept of diet-induced insulin resistance or abnormalities in
insulin metabolism directly contributing to the progression of
symptoms and amyloidosis, relevant to AD, was elegantly demon-
strated in a pivotal study using Tg 2576 mice [15]. Essentially 3- to 4-
month-old female Tg2576 mice were exposed to a high-fat (60% fat,
20% carbohydrate, 20% protein) dietary regime for 5 months relative
to standard laboratory diet (10% fat, 70% carbohydrate and 20%
protein). Importantly both diets contained equal percentages (0.03%)
of cholesterol per gram of diet. At 9 months of age the Tg2576 mice
that had been administered the high-fat diet developed insulin-
resistance (impaired glucose tolerance, increased serum insulin
content and body weight/ependymal fat pad weight) relative to
age-matched Tg2576 exposed to the control diet. Insulin-resistant
Tg2576 mice were also shown to be signiﬁcantly impaired in the
acquisition phase of the Morris water maze, highlighting deﬁcits in
spatial learning relative to age-matched normoglycemic Tg2576mice.
Furthermore, the high-fat diet promoted a N2 fold elevation in Aβ 1–
40 and 1–42 peptide species (measured by ELISA) in the hippocampus
of Tg 2576 mice which was accompanied by a ∼2 fold elevation in
cortical Aβ (6E10-immunopositive) plaque burden. An interrogation
of the potential mechanisms involved with diet-induced insulin
resistance in Tg2576 mice identiﬁed selective alterations in brain
insulin receptor signalling, namely reductions in: insulin-receptor-β
activation; the content of PI3K p85 subunit expression; pS473-AKT/
PKB phosphorylation (reduction in AKT/PKB activation) and pS21-
GSK3α/pS21-GSK3β phosphorylation (indicative of increased GSK3α
and GSK3β activities). Intriguingly the authors further demonstrated
that the level of pS21-GSK3α and pS21-GSK3β activation was strongly
correlated with the generation of the brain CTF-γ cleavage product of
APP (an index of γ-secretase activity), suggesting that insulin
resistance (via a high fat diet) may promote the generation of Aβ in
the CNS. Finally, a signiﬁcant reduction in insulin-degrading enzyme
(IDE) activity and membrane-associated IDE protein content was
observed in the cortex of Tg2576 exposed to a high-fat diet potentially
implicating a reduction in the degradation of Aβ via inhibition of IDE
activity/expression in the CNS. As a follow-up study this research
group [16] then went on to demonstrate an increased expression of
connective tissue growth factor (CTGF) in the CNS of Tg2576 mice
exposed to a high-fat diet correlated with an increasing Aβ plaque
burden. Importantly Zhao et al., [16] showed that the CTGF gene (also
known as insulin growth factor binding protein IGFBP and which has
been implicated in the pathophysiology of diabetes) was elevated
together with protein in the brains of different strains of mice (129/
svJ and Tg2576) with established diet-induced insulin resistance and
was shown to be increased in post-mortem AD brain as a function of
clinical dementia and Aβ neuritic plaques. These results suggest that
CTGF expression in the CNS may signiﬁcantly contribute to Aβ
pathogenesis and cognitive deﬁcits via a mechanism induced in
response to insulin resistance. Therefore this diet-induced insulin-
resistant AD-relevant mousemodel can be viewed to provide a simple
yet physiologically relevant system for evaluating the pathophysio-
logical mechanisms relevant to insulin-resistance and importantly
offers the opportunity for assessing novel therapeutic strategies
associated with insulin and GSK-3 signalling pathways.
Although Tg2576 mice are susceptible to diet-induced insulin
resistance and the development of exacerbated cognitive deﬁcits and
Aβ load and plaque burden, there is evidence to suggest that this APP
mouse line develops insulin-resistance with age without any high fat
dietary manipulation. For example, Pedersen and Flynn [17]
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hyperinsulinemic following an overnight fast and this insulin-resistant
phenotype is effectively reduced to wild-type control levels via the
administration of the PPARγ agonist rosiglitazone (following 4 months
of drug treatment in the diet from 9months of age). Rosiglitazone-
supplemented diet signiﬁcantly reduced the learning and memory
deﬁcits in Tg2576 mice at ∼13 months of age using the 8-arm radial
maze, a task requiring engagement of the hippocampus and cortex and
the regions which show the most severe pathology [18]. Continuous
treatment with rosiglitazone up to ∼16months of age, signiﬁcantly
reduced Aβ1-42 levels in the frontal cortex (via ELISA), increased IDE
gene expression in hippocampal regions (via in-situ hybridization) and
attenuated the reduction in IDE activity in the frontal cortex (125I-insulin
degradation). These results suggest that improving peripheral and/or
central insulin sensitivity may enhance cognitive function and reduce
Aβ pathogenesis in a transgenic mouse model of AD which exhibits an
insulin-resistant background. Importantly these results have some
clinical relevance, in that an alternative PPARγ agonist pioglitazone has
recently been shown to improve cognitive function in mild AD patients
with T2D, suggesting that improving insulin-sensitivity/signalling may
offer therapeutic promise in an enriched (insulin-resistant) sub-
population of AD patients [19].
The utility of the triple-transgenic mouse model (harboring
PS1M146V, APPSwe, and Tau P301L transgenes: 3× Tg) has greatly
facilitated basic research in uncovering novel mechanisms/targets
which contribute to accelerated cognitive deﬁcits, amyloidosis, and
the phosphorylation of tau relevant to AD [20]. Interestingly, a less
aggressive line of 3× Tg mice fed a diet high in saturated and omega-6
fat together with cholesterol for 4 months (from 5 months of age)
increased c-jun N-terminal kinase (JNK) activation, phosphorylated
insulin-receptor substrate 1 (IRS1) and tau relative to control diet
[21]. JNK activation, IRS-1 and tau phosphorylation have been
reported to uncouple insulin signalling which may in part contribute
to a reduced glucose metabolism and utilization consistent with an
insulin resistant phenotype. Interestingly the authors also noted that
if 3× Tg mice were exposed to a high-fat diet and were supplemented
with ﬁsh oil/DHA (docosahexaenoic acid/polyunsaturated fatty acid)
or curcumin (a NF-κβ and JNK inhibitor/polyphenolic anti-inﬂam-
matory agent) or a combination or both for 4 months signiﬁcant
reductions in phosphorylated JNK, IRS-1 and tau together with an
improvement in working-memory cognitive performance (using the
Y-maze) was demonstrated [21]. The results from this study suggest
that pleiotropic effects involving multiple pathways contribute to
insulin-resistance and targeted interventions towards anti-inﬂam-
matory and anti-oxidant pathways may offer potential disease-
prevention and symptom improvement in AD patients. Diets enriched
in DHA have previously been shown to reduce amyloid burden in aged
Tg2576 mice [22] and importantly epidemiological studies suggest an
increased intake of omega-3/DHA can reduce the risk of developing
AD [3,23].
Another dietary manipulation in mice, intake of sucrose-sweet-
ened water, has recently been shown to induce insulin-resistance and
exacerbate cognitive deﬁcits and amyloidosis in the APP/PS1
transgenic mouse model of AD [24]. Exposure of 10% sucrose-
sweetened water or water ad-libitum on a background of a low-fat
rodent diet for 25 weeks to 2 month old APP/PS1 mice resulted in
increased weight gain (through increased total caloriﬁc intake),
impaired glucose tolerance and increased fasting plasma insulin and
lipid (total cholesterol) levels indicative of an insulin-resistant and
hypercholesterolemia phenotype. Furthermore, spatial learning and
memory deﬁcits were apparent in the APP/PS1 transgenic mice
exposed to sucrose-sweetened water and a 2- to 3-fold increase in
total Aβ42 levels (ELISA) and plaque depositionwere observed in the
CNS. No effects on APP transgene expression were shown but a
reduction in IDE (30%) and an increase in ApoE (2.5 fold) levels were
observed in the brains of these mice. The authors hypothesized thatexacerbation of cerebral amyloidosis in sucrose-treated APP/PS1
mice resultedmainly from an increased aggregation of Aβ induced by
the up-regulation of murine ApoE which has been shown to promote
aggregation and ﬁbril formation of Aβ. These results implicate the
chronic consumption of sugar-sweetened beverages could lead to
insulin-resistance independent of dietary fat intake and has clinical
relevance to obesity and cognitive impairments associated with
neurological diseases such as AD. Based on the ﬁndings of this mouse
study and clinical and epidemiological literature [25,26] appropriate
management of excessive consumption of sugar-sweetened bev-
erages may help to offset the development of cognitive deﬁcits and
risk associated with the progression of AD.
A recent study employing of the TgCRN8 (harbouring 3 mutations
in the APP gene i.e. K670M/N671L and V717F) mouse model of AD
evaluated the effects of different dietary compositions on cerebral
amyloidosis and neuronal integrity [27]. Essentially 4 different diets
composed of either high fat/low carbohydrate, high protein/low
carbohydrate, high carbohydrate/low fat or reference chow were
compared for effects on Aβ load and plaque deposition together with
assessment of neuronal density and volume in the hippocampus
from 4 weeks of age. Following 18 weeks of exposure to the diets,
TgCRN8 mice treated with the high-fat/low-carbohydrate diet
exhibited the highest levels of solubilized Aβ42, although this did
not translate into elevated plaque burden. Importantly body weights
were signiﬁcantly elevated from week 6, where high fat/low
carbohydrate induced the highest weight gains in TgCRN8 mice
and this proﬁle continued to the culmination of the study at
18 weeks. No overt differences were shown in markers of neuronal
density or volume with each of the diets, although the high protein/
low carbohydrate diet induced reductions in brain weight and a
tendency for reduced density and volume in the CA3 hippocampal
region of TgCRN8 mice. Unfortunately non-transgenic mice were not
incorporated into the study design so it is difﬁcult to draw too many
conclusions, although the high-fat/low-carbohydrate diet consis-
tently elevated body weight and Aβ levels consistent with other
transgenic mouse models of AD.
As a means to truly test the direct role of neuronal insulin
resistance, as opposed to peripheral insulin resistance via dietary
manipulation, a study evaluating the effects of the neuron-speciﬁc
insulin receptor knockout mouse (NIRKO) were performed [28] to
determine mechanisms and targets that may have relevance to
neurological disorders which harbour an insulin-resistant phenotype
e.g. AD, and may support the concept of a ‘brain’ type 3 diabetes [29].
Importantly NIRKO mice exhibited a complete loss of insulin-
mediated activation of PI3-kinase and markedly reduced phosphor-
ylation of Akt and resulting increased phosphorylation of GSK3β
leading to signiﬁcant phosphorylation of tau, a key neuropathological
hallmark of AD. Although this study went on to conﬁrm no loss of
neuronal integrity, motor or cognitive impairments or CNS glucose
metabolism (via [18F]FDG-micro PET) in the NIRKO mouse, the
authors postulate that this model offers a direct link between
dysfunctional insulin signalling in the brain and Akt, GSK3β and tau
hyperphosphorylation. Unfortunately no measurements of rodent Aβ
were conducted. Importantly this study suggests that although
“neuronal” insulin resistance may be a contributory factor towards
developing AD, additional factors may well interact to generate the
clinical and neuropathological hallmarks of the disease. Further
studies are required to determine how these other/multiple factors
(e.g. over-expression of mutant APP and PS1, dietary manipulation)
may interact with reductions in central insulin signalling to facilitate a
more complete understanding of their relative contributions to
cognitive impairment and neurodegeneration in mouse models of AD.
Impaired metabolic control has also been reported to be a risk
factor for the development Parkinson's disease (PD), particularly at
the onset of midlife adiposity [30] and abdominal obesity in non-
smokers [31]. This epidemiological evidence has been supported by
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spontaneous mutation and high-fat diet) through the administration
of neurotoxins relevant to inducing dopaminergic terminal and cell
death to effectively recapitulate ‘PD-like’ pathology. For example,
Sriram et al., [32] demonstrated that when the dopaminergic
neurotoxin methamphetamine was systemically administered to
female C57BL/6J Lepob (ob/ob) mice at 4–6 months of age, signiﬁcant
mortality was demonstrated compared to lean litter mate controls.
Furthermore, methamphetamine was shown to signiﬁcantly exacer-
bate the neurotoxic phenotype in ob/ob mice compared to lean litter
mate controls, regarding reduced dopamine content, loss of tyrosine
hydroxylase protein and an elevation of GFAP within the striatum.
Importantly, methamphetamine was shown to increase mitochondri-
al uncoupling protein-2 (UCP-2) gene expression within the striatum
of ob/ob mice relative to lean mice (N4.6 fold) suggesting that
oxidative stress and mitochondrial dysfunction may critically con-
tribute to the severe neurotoxic phenotype exhibited by ob/obmice in
this study. More recently, high-fat diet induced obesity has been
shown to enhance the susceptibility of the dopaminergic cell death
and oxidative stress to the classical parkinsonian neurotoxin 1-
Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice [33].
Importantly, the high fat diet (modiﬁed AIN-76A diet with 40% beef
tallow) administered for 8 weeks to C57BL/6 mice signiﬁcantly
decreased levels of striatal dopamine in addition to the reduced
content of tyrosine hydroxylase and microtubule-associated-protein
within the substantia nigra following subtoxic doses of MPTP,
compared to a matched lean group of mice. Interestingly, the levels
of nitrate/nitrate (NOx) were elevated in both plasma and substantia
nigra, while thiobarbituric acid-malondialdehyde adducts were
suppressed within the substantia nigra of obese MPTP-treated mice,
suggesting a systemic inﬂammatory and central oxidative stress/
mitochondrial dysfunction phenotype was observed under these
conditions. Furthermore striatal nNOS phosphorylation and dopamine
turnoverwere increased, while nigralMn-SOD expression and activity
were reduced in obese mice after MPTP treatment, but this
phenomenon was not present in lean mice. Exploration of higher
doses of MPTP increased the mortality rate in obese mice, relative to
lean mice suggesting a reduced tolerability to oxidative stress. These
results suggest that diet-induced obesity may increase the vulnera-
bility of dopaminergic neurons and terminals to neurotoxins such as
MPTP, through enhanced reactive oxygen and nitrogen species
generation with a reduced anti-oxidant capacity. Taken together
these two mouse studies provide supporting evidence to previous
epidemiological studies suggesting a link between obesity/metabolic
stress, dopaminergic dysfunction and Parkinson's disease, although
further studies are required to corroborate this hypothesis.
When comparing data across neurological mouse models that
have incorporated dietary manipulation (high fat diet), it is important
to consider whether the insulin resistant-like phenotype closely
corresponds to classical geneticmousemodels of T2D and obesity. For,
example the db/db mouse model of T2D shows a progressive
deterioration of glycemic control and insulin responsiveness, while
the ob/ob mouse model represents an obese, hyperinsulinemic and
insulin-resistant model which is less severe and viewed to be more
stable than that observed in the db/dbmouse [34]. Importantly when
comparing the results generated from studies employing, for
example, aged Tg2576 APP transgenic mice (e.g. [15] and [17]) with
mouse anti-diabetic efﬁcacy studies using db/db mice (e.g. [35])
appropriate markers such as serum/plasma insulin levels are very
close in magnitude, suggesting comparative levels of insulin resis-
tance. This evidence would suggest that both environmental and
genetic factors may interact in a complex manner and pre-dispose
enhanced susceptibility to insulin-resistance and the progression of
disease. Clearly further work is necessary to determine how target
pathways may overlap between T2D/obesity and ‘AD-like’ mouse
models, for example, in order to determine a more deﬁnitivecharacterization of the causal triggers and contributory factors
involved in the development of disease onset and progression.
In summary, dietary manipulations in mouse models of AD, and to
some extent PD, have greatly supported the clinical epidemiological
evidence suggesting a strong link between high fat/cholesterol and
carbohydrate-rich diets, insulin resistance and the development of
neuropathological hallmarks of disease. As will be covered in the next
section of this review, resveratrol, a putative SIRT1 and AMPK
activator, has been shown to improve insulin sensitivity and longevity
in mice, particularly on an aged and high-caloriﬁc diet background
[36]. Moreover, recent evidence suggests that a reduction in SIRT-1
(mRNA and protein) is closely associated with the accumulation of Aβ
and tau in the brains of AD patients [37], making this target an
attractive focus for further research. The concept of improving health
and neurological diseases through diet management and/or via
modulation of metabolic signalling through new chemical entities
(NCEs) may have important consequences for society in the future,
particularly as obesity, T2D and diseases of ageing are developing at
such a rapid rate.
3. Caloric restriction
Caloric restriction (CR) is the reduction of the average calorie
intake to 50% - 70% of the calories consumed by humans and animals
ad libitum (AL). Its beneﬁcial effects on age related diseases and
indeed aging itself have been postulated for over 60 years [38]. Vice
versa there is mounting evidence that high-calorie input and lack of
exercise are major risk factors for various age-related diseases
including diabetes, cardiovascular diseases and cancer. This highlights
the importance of maintaining metabolic balance on various aspects
of disease onset and progression.
The theory that decreasing the caloric intake can improve
neurological function goes back over 20 years [39,40] and more
recently emerging data from studies on animals and epidemiological
studies has led to the hypothesis that caloric restriction could enhance
cognitive function and be beneﬁcial for preventing neurological
diseases such as Alzheimer's disease (AD), Parkinson's disease (PD),
epilepsy and others.
Several hypotheses on how caloric restriction might be linked to
cognitive capability have been postulated and include anti-inﬂam-
matory mechanisms, reducing neural oxidative stress or promoting
synaptic plasticity. Inducing various neurotrophic/neuroprotective
factors [41] and enhancing neurogenesis [42–44] were also consid-
ered. However, it is very likely that multiple mechanisms underlie the
effect of caloric restriction.
Most of the fundamental work on CR with regards to neurology
and cognitive function in rodents is based on research on rats.
However disease-speciﬁc transgenic mouse models have been widely
used, including models for neurodegenerative diseases like AD, PD
and HD. In addition, model systems for metabolic diseases have been
assessed for deﬁcits in cognitive function. Most, if not all, of these
mouse models have also been used in conjunction with high fat diets.
In contrast to the high fat diet which has a detrimental effect on the
phenotype of some neurological disease models (i.e. notably models
of AD, as described in the previous section), CR has repeatedly been
shown to signiﬁcantly reduce the neurological defects in some of
these disease mousemodels. However data from different sources has
to be analysed carefully, since there are claims that the beneﬁcial
effect of CR is dependent on themetabolic state of the animal and only
if there is an imbalance between energy expenditure and energy
intake can CR then increase life-span [45]. Furthermore it has been
reported that in some cases CR did change behaviour but not cognitive
function, which could lead to dissimilar interpretation [46].
Recent research has provided evidence that CR can alter the
neuropathology in transgenic mouse models for AD. In Tg2576
animals, a mouse model that replicates certain aspects of the
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regulation in the production of amyloid possibly via an activation of
ADAM10, a metalloprotease with α-secretase activity [47]. Two other
AD mouse models with double mutations in the Amyloid precursor
protein (APP; APPswe/ind (J20)) and Presenilin 1 (PS1; APPswe+
PS1M146L), both risk factors for AD, exhibit an early accumulation of
amyloid. In these animals the amyloid load in the cortex and the
amount of glial activation, a marker of inﬂammation, was reduced by
CR [48]. PS1 and PS2 double ko animals, anothermodel of relevance to
AD, show brain atrophy, tau hyperphosphorylation, synaptic dys-
function and cognitive deﬁcits, all hallmarks of AD. In these animals,
long term CR not only signiﬁcantly reduced the tau hyperpho-
sphorylation, apoptosis and neuroinﬂammation but also reduced the
cognitive deﬁcits [49]. A triple transgenic mouse model, in which
overexpressing human cDNAs of APP, PS1 and tau are mutated,
exhibits age-dependent amyloid accumulation and tau phosphoryla-
tion and cognitive deﬁcits in spatial learning tasks. CR and intermitted
fasting (IF), a diet in which animals are food deprived every other day,
can improve the cognitive function, but only following CR was there a
signiﬁcant decrease of amyloid load and tau phosphorylation [50].
This set of data provides evidence that CR can reduce some of the
hallmarks of AD in different animal models and could be beneﬁcial in
the disease.
In a mouse model for PD, in which dopaminergic neurons are
depleted by treatment with MPTP, CR improved motor function and
resulted in neuroprotection. Animals fed with a CR diet performed
signiﬁcantly better on the rotarod, a test for motor function,
compared to the animals on AL diet. Pathological analysis of the
brains of animals fed on a CR diet revealed an increased number of
neurons positive for tyrosine hydrolase (TH), a marker for dopami-
nergic neurons, suggesting a putative neuroprotective effect of CR.
Interestingly, similar results can be achieved by feeding with 2-
deoxyglucose (2-DG), a non-metabolizable form of glucose that
effectively reduces glucose metabolism. How this neuroprotection is
achieved is still not fully understood, however results from dopami-
nergic cell cultures treated with 2-DG suggest a possible mechanism
via a reduction of oxidative stress and preservation of mitochondrial
function. [51]. A study that applied short-term CR after the MPTP
treatment in mice suggests a modulation of the glutamate homeo-
stasis in the striatum as a basis of the neuroprotective effect [52].
Similar effects of CR on neuroprotection were reported in a primate
study, in which monkeys fed on CR diet for 6 months received MPTP
and were analysed over 16–18 weeks. Behavioural analysis combined
with positron emission tomography (PET) and pathological analysis
of the brain led to the conclusion that a beneﬁcial effect of CR on
behaviour and neuroprotection was mediated through up regulation
of neurotrophic factors [53].
There are several reports that show beneﬁcial effects of CR in a
variety of other neurological diseases. For example, fasting has been
described as an anti-seizure therapy for many years [54] and CR was
shown to be beneﬁcial in a mouse model of epilepsy. EL mice, a
genetic model of multifactorial idiopathic epilepsy, present EEG
abnormalities and develop secondary generalized tonic–clonic con-
vulsions. CR diet leads to a delay in onset of seizures for several weeks,
which correlates to blood glucose levels [55,56]. Additional evidence
for CR improving or reversing the disease phenotype has been
provided from research in Sandhoff's disease (SD). SD is a neurode-
generative disease caused by a defective Hexosamidase B gene
resulting in a glycosphingolipid storage disorder. There is evidence
that the neurodegeneration in SD is caused by inﬂammatory effects
likemicroglial activation, macrophage ﬁltration and oxidative damage
which leads to motor dysfunction. Hexosamidase B knock-out mice,
an animal model for SD show develop similar pathology and
symptoms. In response to CR these animals exhibited signiﬁcantly
improved rotarod performance and increased longevity compared to
KO animals on a normal diet [57]. In summary there is increasingevidence of the beneﬁcial effects of CR in a variety of mouse models of
neurological dysfunction.
There are reports that take a more careful approach of evaluating
the data of CR. However it is important to note that, when analysing
the effect of calorie restriction, short-term and long-term deprivation
have to be distinguished. Both can lead to an overall increase in
activity, due to an increased drive and therefore lead to a positive
readout in some cognition paradigms. But only chronic CR leads to a
sustained positive effect on cognition [58].
How the described pro-cognitive effects induced by CR are
mediated is still to be fully discovered, but recent evidence suggests
a modulation of long term potentiation and reduced cytotoxicity in
the hippocampus of rats [59–61]. Recent gene expression studies
usingmicroarrays reveal signiﬁcant gene changes in the brain of aging
mice indicative of activation of pathways involved in inﬂammatory
response, oxidative stress and neurotrophic support and attenuation
of these inmice fedwith CR diet [62]. In a study that analysed the gene
expression changes induced by CR at various ages in the hypothal-
amus, it has been shown that CR induced changes genes occur in an
age-dependent manner. Major pathways modulated were those
involved in brain development and neurogenesis, inﬂammation,
apoptosis and stress responses. Highlighted was the TOR pathway
which is involved in nutrient sensing and has been shown to affect
lifespan via interaction with the Insulin/IGF pathway [63,64].
Another target activated in CR that has been shown to interact
with the Insulin/IGF pathway is SIRT1. SIRT1, the mammalian gene
product of the sir2 gene, is a NAD+ dependent deacetlyase that has
been described as a critical mediator of the effects of CR in
mammalian cells [65] and has been shown to be able to mediate
longevity [66]. Transgenic mice with a brain speciﬁc knock-out of
SIRT1 exhibit a reduction of the beneﬁcial responses to CR[67],
whereas animals over-expressing SIRT1 show some metabolic
similarities to animals on CR [68]. A transgenic mouse model that
allows inducible overexpression of p25, a toxic coactivator of cyclin-
dependent kinase 5, display massive degeneration of forebrain with
features of AD [69,70]. Resveratrol, a polyphenolic SIRT1 activating
compound, injected into the brains of animals 2 weeks after induction
of p25 over-expression was able to prevent the neurodegeneration in
the hippocampus and the impaired associative learning capability of
these animals. Several mechanisms by which SIRT1 promotes this
beneﬁcial effect have been described. The tumor suppressor gene p53
that is important in mediating cell death is deacetylated by SIRT1
rendering it unstable and reducing its expression level suggesting this
molecular target of SIRT1 could explain the neuroprotective effect
[71]. Other reports provide evidence that SIRT1 activation is directly
involved in lowering amyloid by activating α-secretase via suppres-
sion of ROCK1 [72].4. Conclusion
Compelling evidence from mouse models has signiﬁcantly
supported clinical and epidemiological evidence for a strong
association between dietary risk factors, insulin resistance and
neurological disorders such as AD. Importantly these models have
identiﬁed targets and overlapping pathways that may offer future
points of therapeutic intervention. Moreover, the converse concept
of caloriﬁc restriction has also been effectively modeled in mice
offering potential longevity, cognitive remediation and reductions in
pathological markers of disease, via potential improvements in
insulin sensitivity and metabolic homeostasis. Future studies
employing normal and transgenic mice will be essential to conﬁrm
the complex interactions played between a variety of susceptibility
genes and environmental triggers on disease progression and
importantly will help to identify and validate novel therapeutic
agents for disease prevention.
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